Delving into the Latest Updates on Elan Corp. with Synapse

Overview

Purpose To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL). Secondary objectives were to assess the impact of HIV viral control on response and survival, and to correlate MDR-1 expression with outcome. Patients and Methods Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/m2 was given with fixed doses of cyclophosphamide, vincristine, and prednisone every 21 days. All patients received concurrent highly active antiretroviral therapy. NHL tissues were evaluated for multidrug resistance (MDR-1) expression. Results Twenty-four patients were accrued. 67% had high or high-intermediate International Prognostic Index scores; the median CD4 lymphocyte count was 112/mm3 (range, 19/mm3 to 791/mm3). No dose-limiting toxicities were observed at any level, with myelosuppression being the most frequent toxicity. Overall response rate was 88%, with 75% complete responses (CRs), and 13% partial responses. The median duration of CR was 15.6+ months (range, 1.7 to 43.5+ months). Effective HIV viral control during chemotherapy was associated with significantly improved survival (P = .027), but CRs were attained independent of HIV viral control. MDR-1 expression did not correlate with response, suggesting that the liposomal doxorubicin may evade this resistance mechanism. Conclusion Liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is active in AIDS-NHL, with complete remissions achieved in 75% independent of HIV viral control or tissue MDR-1 expression. HIV viral control is associated with a significant improvement in survival. Additional studies are warranted.

01 Jan 1997·Advances in Experimental Medicine and BiologyQ4 · MEDICINE

Impact of IVIVR on Product Development

Q4 · MEDICINE

Article

Author: Devane, J

A review discussion with no references on the role and impact of in vivo-in vitro relationships (IVIVR) on product development particularly as it pertaines to extended release products.

1

News (Medical) associated with Elan Corp.

20 Oct 2024

·www.tipranks.com

M3 Acquires Majority Stake in ELAN Corporation

M3, Inc. has successfully acquired a majority stake in ELAN Corporation through a tender offer, making ELAN a consolidated subsidiary. The tender, which ran from September 20 to October 21, 2024, saw M3 purchasing shares at 1,040 yen each and achieving 55% ownership. This strategic move is expected to enhance M3’s market position and business synergies.

100 Deals associated with Elan Corp.

Login to view more data

100 Translational Medicine associated with Elan Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data